Summary
To characterize publication patterns, collaboration networks, and research
themes in the literature captured by a predefined search on triple-negative breast cancer (TNBC)
chemoresistance.
The Web of Science Core Collection (WoSCC) was searched for English-language
articles and reviews published from January 1, 2015, to December 8, 2025. The query combined
TNBC with cisplatin, paclitaxel, doxorubicin, or gemcitabine and terms related to
chemoresistance and mechanisms. After screening, 212 records were analyzed using CiteSpace,
VOSviewer, and the bibliometrix R package.
Annual output increased from 5 publications in 2015 to 39 in 2025; 92
publications (43.40%) appeared during 2023–2025. China contributed 98 publications (46.23%) but
had lower betweenness centrality (0.15) than the United States (0.34) and India (0.28). Oncology
and biochemistry and molecular biology were the leading disciplines. Keyword and burst analyses
identified persistent attention to chemoresistance, apoptosis, and signaling pathways, with
recent activity in proliferation, gene expression, and phosphorylation. Nanomedicine and
metabolism appeared as research themes, but the bibliometric data do not establish clinical
efficacy.
TNBC chemoresistance research develops rapidly. Current studies focus on
molecular mechanisms and novel therapies. This study constitutes an exploratory bibliometric
analysis based on 212 records from the Web of Science Core Collection; however, it does not
represent the entirety of the literature on chemotherapy resistance in TNBC. It is necessary to
strengthen international cooperation. Its findings describe research activity rather than
treatment effectiveness and should not be generalized to all TNBC systemic therapies.
Keywords
TNBC, chemoresistance, bibliometric analysis, drug resistance mechanism
Introduction
Breast cancer is the most frequently diagnosed cancer in women worldwide and
remains a leading cause of cancer mortality
1
.
Triple-negative breast cancer (TNBC) is defined by the absence of estrogen receptor,
progesterone receptor, and human epidermal growth factor receptor 2 expression. It accounts for
approximately 10–15% of breast cancers and is characterized by marked molecular heterogeneity,
early recurrence, and limited subtype-specific treatment options2,
3
. Cytotoxic chemotherapy—principally
anthracycline-, taxane-, and platinum-containing regimens—remains a major component of systemic
treatment, although treatment choices vary by disease stage and biomarker status4,
5
. Intrinsic or acquired chemoresistance limits
durable response and contributes to relapse and metastatic progression5,
6,
7,
8,
9
.
Bibliometric analysis quantitatively describes publication output, citation
structure, collaboration, and thematic evolution. When transparently reported, it can
complement—but does not replace—systematic reviews or clinical evidence synthesis
10,
11
. CiteSpace and VOSviewer support
co-citation, co-occurrence, and network mapping, whereas bibliometrix provides complementary
descriptive analyses12,
16
.
This study mapped the literature captured by a prespecified Web of Science
search on TNBC chemoresistance from 2015 through 2025. This study applied bibliometric
methodologies to systematically analyze and integrate research on the mechanisms of
chemoresistance in TNBC. The results elucidate the current research landscape, major thematic
concentrations, and emerging trends in this field. The scope was chemoresistance associated with
four named cytotoxic agents (cisplatin, paclitaxel, doxorubicin, and gemcitabine).
Immune-evasion and immunotherapy-related findings are discussed only when they intersect with
mechanisms of response to cytotoxic treatment; resistance to immune-checkpoint inhibitors as an
independent treatment category was not comprehensively searched and is outside the primary
scope. The analysis therefore identifies patterns within the retrieved corpus rather than
providing an exhaustive account of all treatment resistance in TNBC.
Materials and Methods
Literature search and search strategy
The Web of Science Core Collection (WoSCC; https://www.webofscience.com)
was searched using the following query: TS=(("triple negative breast cancer" OR TNBC) AND
(cisplatin OR paclitaxel OR doxorubicin OR gemcitabine) AND (chemoresistance OR "acquired
resistance") AND (mechanisms OR pathways)). Filters were document type (Article or Review),
language (English), and publication date (January 1, 2015, to December 8, 2025). The search
returned 267 records. One researcher conducted the preliminary screening, and uncertain
records were resolved through discussion with a second researcher; 212 records met the
eligibility criteria. It should be noted that this study did not employ an independent
dual-reviewer screening protocol. Instead, one researcher conducted an initial screening of
titles and abstracts to exclude records that clearly did not meet the inclusion criteria,
including non-articles/reviews, non-English language documents, irrelevant studies, and
records with incomplete bibliographic data; for records whose eligibility status was
unclear, the first researcher consulted a second researcher, and a final consensus was
reached through discussion. In this phase, a total of 55 records were excluded.
Subsequently, an internal deduplication step was performed using CiteSpace, during which no
duplicate records were identified (n=0).
These four cytotoxic chemotherapeutic agents (cisplatin, paclitaxel, doxorubicin,
gemcitabine) were predefined as search entries in the initial study design. They represent
the most commonly used first‑line conventional chemotherapeutic agents for TNBC and were
selected as core drugs in previously published bibliometric studies of TNBC chemoresistance.
We acknowledge that this drug set excludes carboplatin, eribulin, capecitabine,
antibody‑drug conjugates and other newer agents, which inevitably restricts the scope of our
corpus.
Inclusion and exclusion criteria
Eligible records were peer-reviewed research articles or reviews,
written in English, published within the prespecified date range, and addressing TNBC
chemoresistance or its mechanistic pathways within the operational search scope.
Records were excluded if they were duplicates; were unrelated to TNBC chemoresistance;
lacked essential bibliographic information, such as author or institutional data; were
conference proceedings, books, guidelines, news items, or other nonjournal material; or had
been retracted.
Data processing and visualization analysis
Bibliographic records were imported into CiteSpace 6.4.R1, VOSviewer
1.6.20, and R with bibliometrix 5.2.1. Duplicate records were removed before analysis.
Annual output, countries/regions, institutions, authors, journals, disciplines, references,
and keywords were analyzed. Excel 2024 was used for data organization and line charts.
VOSviewer analyses used full counting. A similarity threshold of 0.1 was
applied, and nodes with an occurrence frequency of at least 2 were retained for
collaboration-network construction.
The CiteSpace output embedded in the manuscript documented a 2015–2025 time span with a
1-year slice length and g-index selection (k=25), with LRF=2.5, L/N=10, LBY=5, and e=1.0.
Cosine similarity was used for link strength, and the displayed networks were generated
without pruning. These settings were applied to the reported co-occurrence, co-citation, and
collaboration visualizations.
In the visualizations, node size represents frequency, link thickness represents
relationship strength, and node color indicates the time of occurrence. Nodes with
betweenness centrality of at least 0.10 are highlighted by a purple rim. Modularity Q and
weighted mean silhouette S were used to assess keyword-cluster structure.
International collaboration rate was calculated as the number of publications coauthored
across countries divided by 212 and multiplied by 100%. Interinstitutional collaboration
rate was calculated as the number of publications coauthored across institutions divided by
212 and multiplied by 100% (Figure 1).
Results
Publication trends
The search identified 267 records, of which 212 articles and reviews
published between 2015 and 2025 were retained (Figure 2). The 92
publications issued during 2023–2025 represented 43.40% of the 212-record corpus (Figure 2B), indicating a recent increase in publication activity.
Disciplines and journals
The included publications span 32 disciplinary categories, among which
oncology, biochemistry and molecular biology, and cell biology constitute the three core
disciplines. Among these, biochemistry and molecular biology exhibit the highest betweenness
centrality, indicating that it plays a pivotal bridging role in interdisciplinary
integration (Figure 3). The records appeared in 126 journals, The top 10
journals by number of publications accounted for 21.69% of the total number of publications
(Table 2). In the journal co-citation analysis, Cancer Research
occupies a central position with the highest co-citation frequency (Figure
4).
Table 2. Top 10 journals by publication count and top 10
co-cited journals by citation count.
| Rank |
Journal |
Count |
IF/JCR |
Rank |
Cited Journal |
Citations |
Centrality |
IF/JCR |
| 1 |
Cavcers |
7 |
4.4/Q2 |
1 |
Cancer Research |
158 |
0.03 |
16.6/Q1 |
| 2 |
Frontiers in Oncology |
6 |
3.3/Q2 |
2 |
Oncogene |
144 |
0.01 |
7.3/Q1 |
| 3 |
Cell Death & Disease |
5 |
9.6/Q1 |
3 |
Clinical Cancer Research |
116 |
0.03 |
10.2/Q1 |
| 4 |
International Journal of Molecular Sciences |
4 |
4.9/Q1 |
4 |
Proceedings of the National Academy of Sciences of the United States of America
(PNAS) |
109 |
0.04 |
9.1/Q1 |
| 5 |
Cell Death Discovery |
4 |
7.0/Q1 |
5 |
Oncotarget |
108 |
0.02 |
5.1/Q2* |
| 6 |
Oncotarget |
4 |
5.1/Q2* |
6 |
Journal of Biological Chemistry |
99 |
0.02 |
3.9/Q2 |
| 7 |
Oncogene |
4 |
7.3/Q1 |
7 |
Nature |
98 |
0.02 |
48.5/Q1 |
| 8 |
Neoplasia |
4 |
7.7/Q1 |
8 |
Cell |
97 |
0.02 |
42.5/Q1 |
| 9 |
PLOS ONE |
4 |
2.6/Q2 |
9 |
PLOS ONE |
94 |
0.02 |
2.6/Q2 |
| 10 |
Breast Cancer Research |
4 |
5.6/Q1 |
10 |
International Journal of Molecular Sciences |
94 |
0.03 |
4.9/Q1 |
Note: The
evaluation was based on the 2023 JCR. When multiple categories had inconsistent results in
the JCR quartile, the result from the highest-ranked quartile was selected.
Countries / Regions / Institutions / Authors / Collaborations
The 212 records included 1,724 authors from 422 institutional entries
across 47 countries/regions. China contributed 98 records (46.23%), the United States 47
(22.17%), and India 17 (8.02%) (Table 3). Country/region labels were
standardized for presentation; Taiwan is reported as Taiwan, China, while its counts and
network metrics remain separate from those for mainland China because the original network
was not rerun after geographic relabeling.
Table 3. Top 10 countries/regions and authors by publication
count.
| Rank |
Countries/regions |
Count |
Centrality |
Rank |
Authors |
Count |
| 1 |
China |
98 |
0.15 |
1 |
Yaming Li |
7 |
| 2 |
USA |
47 |
0.34 |
2 |
Qifeng Yang |
7 |
| 3 |
India |
17 |
0.28 |
3 |
Wenjing Zhao |
6 |
| 4 |
Italy |
10 |
0.02 |
4 |
Yiran Liang |
6 |
| 5 |
Canada |
8 |
0.02 |
5 |
Dan Luo |
5 |
| 6 |
Taiwan, China |
7 |
0.00 |
6 |
Lijuan Wang |
5 |
| 7 |
Germany |
7 |
0.06 |
7 |
Bing Chen |
4 |
| 8 |
Egypt |
7 |
0.03 |
8 |
Dianwen Han |
4 |
| 9 |
England |
7 |
0.12 |
9 |
Shekhar, Malathy P |
4 |
| 10 |
Spain |
6 |
0.03 |
10 |
Yuhua Jin |
2 |
Note: Taiwan is
reported as Taiwan, China. Its publication count and centrality remain separate from
mainland China because the original collaboration network was not recomputed after label
standardization.
Table 4. Top 10 institutional entries by publication count.
| Rank |
Institutions |
Count |
Centrality |
| 1 |
Chinese Academy of Sciences |
6 |
0.00 |
| 2 |
Egyptian Knowledge Bank (EKB) |
6 |
0.00 |
| 3 |
Harvard University |
5 |
0.00 |
| 4 |
Central South University |
5 |
0.00 |
| 5 |
Harbin Medical University |
5 |
0.00 |
| 6 |
Barbara Ann Karmanos Cancer Institute |
5 |
0.00 |
| 7 |
Fudan University |
5 |
0.00 |
| 8 |
Harvard Medical School |
4 |
0.00 |
| 9 |
Academia Sinica, Taiwan, China |
4 |
0.00 |
| 10 |
Guangzhou University of Chinese Medicine |
4 |
0.00 |
Note:
Institutional names are shown as indexed in WoSCC. Affiliation variants, including Harvard
University, Harvard Medical School, and Harvard University Medical Affiliates, were not
merged; rankings and centrality values should therefore be interpreted as entry-level rather
than organization-level metrics.
The country/region collaboration network contained 47 nodes and 92
links, with a density of 0.0851 (Figure 5). The United States
(centrality 0.34), India (0.28), China (0.15), and England (0.12) had the highest
betweenness centralities among the leading contributors (Table 3).
China had the largest publication count, whereas the United States occupied the most central
bridging position in the network.
The largest bilateral publication count was observed between China and
the United States (10 records, Figure 6). The network metrics describe
connectivity but do not identify its causes. Nevertheless, the combination of high output
and modest centrality suggests limited cross-network integration, which may reduce
opportunities for independent replication, cross-population validation, and coordinated
multicenter research.
At the institutional level, network density was 0.0163, and the 10 most
productive institutional entries each had centrality reported as 0.00 (Table 4; Figure 7). These values do not support
describing any institution as a coordinating hub. They may also be affected by
unstandardized affiliation strings; for example, Harvard University, Harvard Medical School,
and Harvard University Medical Affiliates appear as separate nodes.
The most productive institutional entries were the Chinese Academy of
Sciences and Egyptian Knowledge Bank (EKB), with 6 records each (2.83%), followed by Harvard
University, Central South University, and Harbin Medical University, with 5 records each
(2.36%) (Table 4). These rankings reflect the affiliations as indexed
in WoSCC and should not be interpreted as institution-level performance measures.
The most productive authors were Yaming Li and Qifeng Yang (7 records
each; 3.30%), Wenjing Zhao and Yiran Liang (6 each; 2.83%), and Dan Luo and Lijuan Wang (5
each; 2.36%) (Table 3; Figure 8). Representative
publications from these groups addressed noncoding RNA and endoplasmic-reticulum-stress
mechanisms of chemoresistance
13,
14
. The dispersed author network indicates
that productivity was concentrated in small teams rather than a single field-wide
collaboration hub.
Keyword analysis
The 30 most frequent keywords are listed in Table 5.The keywords revolve
around disease phenotypes, chemotherapy resistance, and biological processes such as
apoptosis, metastasis, and signaling pathway regulation. Ten keywords exhibited high
centrality (≥0.10), forming the structural backbone of the research network (Table 5, Figure 9).
Table 5. Top 30 keywords by occurrence frequency.
| Rank |
Keywords |
Count |
Year |
Centrality |
Rank |
Keywords |
Count |
Year |
Centrality |
| 1 |
expression |
74 |
2015 |
0.07 |
16 |
doxorubicin |
21 |
2018 |
0.09 |
| 2 |
TBNC |
46 |
2018 |
0.09 |
17 |
pathway |
20 |
2016 |
0.11 |
| 3 |
breast cancer |
43 |
2015 |
0.27 |
18 |
therapy |
17 |
2016 |
0.07 |
| 4 |
chemotherapy |
41 |
2015 |
0.09 |
19 |
proliferation |
14 |
2021 |
0.04 |
| 5 |
drug resistance |
38 |
2015 |
0.18 |
20 |
multidrug resistance |
14 |
2018 |
0.04 |
| 6 |
resistance |
34 |
2017 |
0.08 |
21 |
stem cells |
13 |
2016 |
0.02 |
| 7 |
metastasis |
31 |
2015 |
0.13 |
23 |
cisplatin resistance |
12 |
2015 |
0.03 |
| 8 |
apoptosis |
30 |
2015 |
0.13 |
23 |
cisplatin resistance |
12 |
2015 |
0.03 |
| 9 |
chemoresistance |
27 |
2015 |
0.14 |
24 |
gene expression |
11 |
2019 |
0.02 |
| 10 |
metastasis |
26 |
2016 |
0.10 |
25 |
epithelial mesenchymal transition |
11 |
2018 |
0.02 |
| 11 |
inhibition |
26 |
2015 |
0.14 |
26 |
growth |
11 |
2015 |
0.08 |
| 12 |
activation |
26 |
2016 |
0.10 |
27 |
identification |
9 |
2015 |
0.03 |
| 13 |
triple negative breast cancer |
23 |
2017 |
0.10 |
28 |
phosphorylation |
9 |
2017 |
0.02 |
| 14 |
survival |
23 |
2015 |
0.06 |
29 |
in vitro |
8 |
2015 |
0.03 |
| 15 |
mechanisms |
21 |
2018 |
0.10 |
30 |
molecular mechanisms |
8 |
2017 |
0.06 |
Ten keywords had betweenness centrality of at least 0.10: breast
cancer (0.27), cells (0.19), drug resistance (0.18), chemoresistance (0.14), inhibition
(0.14), apoptosis (0.13), pathway (0.11), metastasis (0.10), activation (0.10), and
triple-negative breast cancer (0.10) (Figure 9). These values identify structurally
connected terms within the corpus; they do not measure biological importance or therapeutic
efficacy.
CiteSpace identified 11 keyword clusters, labeled #0 through #10:
nanomedicine (#0), Wnt signaling (#1), chemotherapy resistance (#2), drug resistance (#3),
pathway (#4), triple-negative breast cancer (#5), proliferation (#6), ovarian cancer (#7),
confers resistance (#8), breast cancer (#9), and atezolizumab (#10) (Figure
10). It is noteworthy that the atezolizumab cluster (#10) was derived from keyword
co-occurrence analysis in the literature retrieved using a search strategy targeting four
specified cytotoxic agents. Since no specialized immunotherapy-related search terms were
included in the search strategy, this cluster solely reflects the intersection between
immunotherapy-related literature and literature on chemotherapy resistance. Cluster quality
was moderate (modularity Q=0.411) with acceptable within-cluster consistency (weighted mean
silhouette S=0.7228).
The keyword timeline (Figure 11) shows
persistent attention to chemotherapy, chemoresistance, drug resistance, and breast cancer
across the study period. Mechanistic themes, including Wnt signaling, epithelial–mesenchymal
transition, stem cells, metabolism, and phosphorylation, appeared alongside
treatment-oriented themes such as nanomedicine and atezolizumab. The appearance of
atezolizumab represents an adjacent immunotherapy topic within the retrieved corpus; because
immune-checkpoint inhibitors were not dedicated search terms, the analysis cannot
characterize the full literature on immunotherapy resistance.
Burst analysis (Figure 12) identified
chemoresistance as the strongest burst term (strength 3.02; 2018–2019). Other notable bursts
included multidrug resistance (2.84; 2020–2021), metabolism (2.79; 2022–2023), proliferation
(2.63; 2022–2025), cisplatin resistance (2.46; 2015–2017), and mechanisms (2.22; 2020–2022).
Terms with bursts continuing through 2025 included proliferation, gene expression (1.82),
phosphorylation (1.60), carcinoma (1.07), identification (0.85), and survival (0.62).
The 2019 study by Echeverria et al. was the most cited article in
the corpus (221 citations at data extraction) and described a reversible drug-tolerant state
after neoadjuvant chemotherapy in TNBC
22
.
In PDX models, pharmacologic inhibition of oxidative phosphorylation (OXPHOS) with
IACS-010759 delayed residual-tumor regrowth; the study did not demonstrate clinical cure. A
separate 2021 preclinical study identified OXPHOS as a metabolic vulnerability and reported
tumor stabilization or enhanced activity of selected combinations in TNBC xenograft models
15
.
Citation-burst strength quantifies a temporary increase in
attention to a term or reference
16
. In
this analysis, burst timing distinguishes earlier topics, such as cisplatin resistance and
chemoresistance, from recent topics, such as proliferation, gene expression, and
phosphorylation (Figure 12).
These keyword patterns reflect shifts in research focus rather
than clinically actionable evidence. Metabolism, nanomedicine, and phosphorylation emerged
as key research hotspots in this literature analysis. The majority of studies addressing
these topics were preclinical investigations, lacking robust clinical evidence; thus,
further clinical trials are required for validation. This analysis cannot confirm their
clinical translational value. Clinical utility would necessitate prospective validation,
estimation of treatment-specific effects, safety assessments, and comparisons with
established treatment regimens—outcomes that cannot be inferred from keyword frequency or
term emergence.
Literature and reference analysis
The most highly cited article focuses on the reversible drug-tolerant
state following neoadjuvant chemotherapy in TNBC, validated using PDX models and clinical
samples
22
. Other high-impact studies have
explored mechanisms such as tumor cell–macrophage crosstalk and ferroptosis17
, as well as summarized the signaling
pathways in TNBC targeted by natural products21
(Table 6). These high-impact studies delineate the core
mechanistic themes in this field; however, their citation counts reflect academic interest
rather than methodological rigor or the level of clinical evidence.
Table 6. Top 10 articles by citation count at data
extraction.
| Rank |
Year |
Title |
Journal |
First Author |
Country |
Citations |
| 1 |
2019 |
Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated
by a reversible drug-tolerant state |
Science Translational Medicine |
Gloria V Echeverria |
USA |
221 |
| 2 |
2022 |
HLF regulates ferroptosis, development and chemoresistance of triple-negative
breast cancer by activating tumor cell-macrophage crosstalk |
Journal of Hematology & Oncology |
Pinghua Li |
China |
201 |
| 3 |
2021 |
The signalling pathways and targets of traditional Chinese medicine and natural
medicine in triple-negative breast cancer |
Journal of Ethnopharmacology |
Yang Z |
China |
186 |
| 4 |
2016 |
Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of
BRCA1-Deficient Breast Cancer |
Journal of the National Cancer Institute |
Petra ter Brugge |
Netherlands |
162 |
| 5 |
2020 |
Targeting Glucose Metabolism to Overcome Resistance to Anticancer Chemotherapy
in Breast Cancer |
Cancers |
Varghese, E |
Qatar |
161 |
| 6 |
2018 |
MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast
cancer via direct targeting of STMN1 |
Cell Death & Disease |
Yaming Li |
China |
151 |
| 7 |
2022 |
Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy
Resistant TNBC |
International Journal of Molecular Sciences |
Paola Ferrari |
Italy |
140 |
| 8 |
2022 |
CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin
resistance in TNBC by destabilizing PKR |
Journal of Hematology & Oncology |
Xiaolong Wang |
China |
138 |
| 9 |
2020 |
Akt-targeted therapy as a promising strategy to overcome drug Resistance in
breast cancer - A comprehensive review from chemotherapy to immunotherapy |
Pharmacological Research |
Parham Jabbarzadeh Kaboli |
China |
127 |
| 10 |
2018 |
Appraising the "entourage effect": Antitumour action of a pure cannabinoid
versus a botanical drug preparation in preclinical models of breast cancer |
Biochemical Pharmacology |
Sandra Blasco-Benito |
Spain |
126 |
Within the co-citation reference network, two classic reviews on
the mechanisms of chemotherapy resistance in TNBC exhibit the highest betweenness
centrality, serving as pivotal knowledge bridges that connect diverse research domains (Table 7, Figure 13).
In the reference co-citation network (Figure
13)), Nedeljković and Damjanović (2019) and O'Reilly et al. (2015) each had
centrality of 0.41 among the top 10 references (Table 7). These works
therefore combined frequent co-citation with bridging positions in the network.
Table 7. Top 10 co-cited references by citation count.
| Rank |
Year |
Title |
Journal |
First Author |
Country |
Citations |
Centrality |
| 1 |
2021 |
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality
Worldwide for 36 Cancers in 185 Countries. |
CA: A Cancer Journal for Clinicians |
Hyuna Sung |
USA |
19 |
0.04 |
| 2 |
2019 |
Mechanisms of Chemotherapy Resistance in TNBC-How We Can Rise to the Challenge
|
Cells |
Milica Nedeljković |
Serbia |
16 |
0.41 |
| 3 |
2015 |
The fate of chemoresistance in triple negative breast cancer (TNBC) |
BBA Clinical |
Elma An O'Reilly |
Ireland |
13 |
0.41 |
| 4 |
2022 |
Recent advances in therapeutic strategies for TNBC |
Journal of Hematology & Oncology |
Yun Li |
China |
9 |
0.02 |
| 5 |
2020 |
TNBC molecular subtyping and treatment progress. |
Breast Cancer Research |
Yin Li |
China |
9 |
0.08 |
| 6 |
2022 |
Treatment landscape of TNBC - expanded options, evolving needs. |
Nature Reviews Clinical Oncology |
Giampaolo Bianchini |
Italy |
8 |
0.02 |
| 7 |
2019 |
Insights into Molecular Classifications of TNBC: Improving Patient Selection for
Treatment. |
Cancer Discovery |
Ana C Garrido-Castro |
USA |
7 |
0.00 |
| 8 |
2023 |
Cancer statistics, 2023 |
CA: A Cancer Journal for Clinicians |
Rebecca L Siegel |
USA |
6 |
0.00 |
| 9 |
2016 |
TNBC: challenges and opportunities of a heterogeneous disease |
Nature Reviews Clinical Oncology |
Giampaolo Bianchini |
Italy |
6 |
0.07 |
| 10 |
2021 |
Doxorubicin-Resistant TNBC Cells Exhibit Rapid Growth with Cancer Stem Cell-like
Properties and EMT Phenotype, Which Can Be Transferred to Parental Cells through
Autocrine Signalling |
International Journal of Molecular Sciences |
Anjugam Paramanantham |
Korea |
5 |
0.01 |
Five references showed the strongest citation bursts (Figure 14)): Sung et al. (strength 5.75; 2022–2025), O'Reilly et al.
(5.20; 2017–2020), Nedeljković and Damjanović (4.66; 2021–2025), Garrido-Castro et al.
(3.30; 2023–2025), and Qin et al. (2.06; 2021–2022). The reference timeline and cluster map
are shown in Figure 15) and 16).
Discussion
Basic information
TNBC is clinically and molecularly heterogeneous, and cytotoxic
chemotherapy remains central to treatment in both early and advanced disease, although
contemporary care increasingly incorporates biomarker-directed agents
18,
19,
23
. Resistance is treatment- and
context-specific; mechanisms identified for one drug, model, or disease stage should not be
generalized without validation.
Across cancers, chemoresistance can involve altered drug
transport and metabolism, enhanced DNA-damage repair, apoptosis avoidance, phenotypic
plasticity, cancer stem-cell programs, and interactions with the tumor microenvironment
20
. Bibliometric analysis can identify which
of these themes attract attention, but it cannot quantify their causal contribution or
establish the effectiveness of an intervention.
Hotspots and frontiers
Research structure and collaboration
This study is not the first bibliometric analysis of TNBC.
Hao et al. mapped 2000–2020 TNBC literature broadly
30
, whereas the present analysis narrows the question to
a 2015–2025 corpus retrieved with chemoresistance and four cytotoxic-drug terms. This
narrower scope provides more specific information on chemoresistance-related themes but
also reduces coverage and precludes claims about the entire TNBC treatment landscape.
The country network combined high output from China with
greater bridging centrality for the United States and India. The bibliographic data
cannot determine whether this pattern arose from language, funding, or scientific
priorities. A cautious interpretation is that the field remains partitioned across
national and institutional groups. More transparent data sharing, harmonized
experimental definitions, and cross-site validation would reduce duplicated effort and
improve the generalizability of mechanistic findings.
The most visible mechanistic contributions in the corpus
included noncoding-RNA regulation
13,
24,
25
, endoplasmic-reticulum stress14
, ferroptosis and macrophage crosstalk
17
, reversible drug tolerance and
OXPHOS15,
22
, stromal remodeling and cancer
stem-cell plasticity26
, and EMT in
doxorubicin-resistant cells27
. The
co-citation prominence of the reviews by Nedeljković and Damjanović and O'Reilly et al.
further indicates sustained attention to multifactorial chemoresistance28,
29
. These themes are consistent with
the keyword clusters, but most supporting studies are preclinical.
Hotspots, mechanistic themes, and translational limits
The bibliometric results support three connected themes. First,
the chemotherapy-resistance and drug-resistance clusters (#2 and #3) form the clinical
problem around which the network is organized. Second, Wnt signaling, pathway,
proliferation, apoptosis, EMT, and cancer stem cells (CSCs) represent mechanistic work on
tumor-cell survival and plasticity. Third, nanomedicine and atezolizumab represent
treatment-oriented extensions. This structure links the discussion directly to the cluster,
timeline, and burst results.
Experimental studies illustrate the mechanistic theme but also its evidentiary limits.
Stromal Hedgehog signaling promoted a chemoresistant CSC phenotype in TNBC models, and
stromal targeting sensitized xenografts to docetaxel
26
. Doxorubicin-resistant TNBC cells acquired EMT and
CSC-like features in a single-cell-line model27
Paclitaxel-induced extracellular vesicle signaling was associated with reduced
chemosensitivity in experimental breast-cancer systems32
. These findings are biologically coherent with the
keyword network, but they do not establish population-level benefit or a standard clinical
strategy.
Immune-evasion and tumor-microenvironment literature intersects with
chemoresistance because immune and stromal cells can alter tumor survival and drug exposure
33,
34,
35,
36
. However, immune-checkpoint inhibitor
resistance is a distinct clinical question with dedicated biomarkers and treatment-specific
evidence38
. The atezolizumab cluster should
therefore be interpreted as an adjacent topic in this corpus.
Nanomedicine is the most prominent keyword cluster (#0), indicating
ongoing publication activity in the areas of drug delivery and chemotherapy resistance
research. The majority of studies incorporating nanomedicine are preclinical investigations,
lacking robust clinical evidence; therefore, further clinical trials are required for
validation. This analysis cannot confirm its clinical translational value. Previous reviews
have described strategies targeting CSCs, optimizing drug delivery, and reducing systemic
exposure
31,
37
; however, these reviews primarily
encompass preclinical and early translational studies. The prominence of a keyword does not
substantiate clinical efficacy, safety, manufacturability, or cost-effectiveness; thus,
claims of clinical applicability should not be made based on this evidence alone.
Implications and future research
The results support methodological priorities rather than treatment
recommendations. Future studies should prespecify drug-specific resistance definitions,
distinguish intrinsic from acquired resistance, report TNBC molecular subtype and disease
stage, and connect laboratory models to prospectively collected clinical samples.
International and interinstitutional collaborations could facilitate external validation and
multicenter replication. Notably, treatment-oriented themes—including metabolic inhibition,
biomarkers, and nanomedicine—represent research hotspots identified in this literature
review analysis; however, these areas still lack robust clinical validation and should be
advanced through staged preclinical validation and properly designed clinical trials.
Methodological context and comparison with prior bibliometric work
Bibliometric methods describe the structure and evolution of a
literature base through publication, citation, and network data
10,
11,
12,
16
. They complement systematic reviews but
do not synthesize intervention effects or grade clinical evidence.
The most closely related prior work is the panoramic bibliometric
mapping of the entire TNBC research field conducted by Hao et al.
30
, which analyzed 1904 publications retrieved from WoSCC
between 2000 and 2020. To elucidate the incremental contributions and scope boundaries of
this study, we systematically compared these two works along their core dimensions, as
summarized in Table 8.
Table 8. Comparison between this study and the broad TNBC
bibliometric analysis by Hao et al. (2022).
| Dimension |
Hao et al. (2022) |
This study |
| Core research scope |
Entire TNBC research field (all topics) |
Chemoresistance mechanisms of four specified cytotoxic agents |
| Time span |
2000–2020 |
2015–2025 |
| Number of included publications |
1904 |
212 |
| Database source |
Web of Science Core Collection |
Web of Science Core Collection |
| Analytical tools |
CiteSpace, VOSviewer |
CiteSpace, VOSviewer, bibliometrix |
| Core thematic clusters |
Metastasis, EGFR, lncRNA, immunotherapy, targeted therapy |
Nanomedicine, Wnt signaling, chemotherapy resistance, drug resistance,
proliferation |
| Country-level pattern |
China ranked first in output; USA had highest betweenness centrality |
China ranked first in output; USA had highest betweenness centrality |
| Key emerging topics (by end of study period) |
Immunotherapy, liquid biopsy, ferroptosis |
Proliferation, gene expression, phosphorylation, metabolism |
Regarding specific differences, previous studies have provided a
comprehensive overview of the field of TNBC research, whereas this study specifically
narrows its scope to the chemoresistance mechanisms of four conventional cytotoxic drugs,
thereby offering a more focused presentation of the thematic characteristics of this
specialized subfield. Furthermore, this study extends the observation window by five years,
up to 2025, capturing recent research trends and emerging focal points—including
proliferation, gene expression, and phosphorylation—which were not sufficiently evident in
earlier datasets spanning 2000–2020. The thematic structure identified in this study centers
on drug resistance and its underlying mechanistic pathways, distinguishing it from the
broader cluster sets identified in the comprehensive field analysis. Correspondingly, this
narrower search scope means that these findings do not represent the full spectrum of TNBC
research across all subtypes, treatment modalities, and clinical settings. However, the
consistent national-level patterns observed across both studies—namely, the highest number
of publications in China and the highest network centrality in the United States—indicate
that these patterns constitute a stable structural feature within the broader TNBC research
ecosystem.
Journal impact factors and quartiles provide journal-level
context but do not measure the quality of individual studies
39,
40
. Similarly, citation counts are
time-dependent and may favor older publications. Accordingly, journal and citation rankings
in this study are descriptive indicators only.
Limitations
This study has several limitations. First, it used only WoSCC and
included only English-language articles and reviews; relevant records indexed exclusively in
PubMed, Scopus, Embase, or non-English sources may have been missed. Second, the query
specified cisplatin, paclitaxel, doxorubicin, and gemcitabine and did not include other
clinically used agents or emerging treatment classes as dedicated terms. The findings
therefore apply to the retrieved corpus rather than the complete literature on TNBC
treatment resistance. In addition, all network analyses in this study directly used the
original indexed affiliation fields exported from the WoSCC. The affiliation names were not
standardized, so the affiliation-related results should be interpreted with caution.
Third, no alternative-query, date-window, or database sensitivity
analysis was performed. Fourth, institution and author names were analyzed as indexed;
affiliation variants may have split a single organization into multiple nodes and
contributed to the centrality values of 0.00 in Table 4. Fifth, citation counts, impact
factors, and network topology are time-dependent and sensitive to database coverage and
parameter settings. Finally, keyword frequency, clustering, and burst detection measure
research attention, not causal importance, treatment efficacy, clinical maturity, or
cost-effectiveness. Notably, this study did not perform stratified analyses according to the
molecular subtypes of TNBC, individual drug types, experimental versus clinical studies,
disease stages, or clinical trial outcomes, so it is difficult to provide targeted clinical
guidance.
Conclusion
As an exploratory bibliometric analysis based on 212 publications retrieved
from the WoSCC, this study delineates the research landscape of chemotherapy resistance
mechanisms in TNBC within a specific search scope; however, it does not represent the entirety
of the literature on TNBC chemotherapy resistance. Publication activity in this field has
increased substantially from 2015 to 2025, with a marked acceleration in recent years. Within
the 212-record WoSCC corpus captured by the prespecified English-language, four-drug search,
publication activity on TNBC chemoresistance increased substantially from 2015 to 2025. China
contributed the largest number of records, whereas the United States had the highest
country-level betweenness centrality; institutional centrality remained low. This article
addresses chemotherapy resistance, signaling pathways, apoptosis, proliferation, and cancer cell
plasticity; more recently, it has also focused on gene expression, phosphorylation, metabolism,
and nanomedicine. Notably, phosphorylation, metabolism, and nanomedicine have been identified as
research hotspots in this literature analysis. Regarding the inclusion of these topics in
existing studies, the majority involve preclinical research, lacking robust clinical evidence;
therefore, further clinical trials are needed for validation. This analysis cannot confirm their
clinical translational value. These findings systematically delineate the current research
activities and unmet needs in this field, yet they do not establish clinical efficacy. Broader
multi-database searches, drug- and subtype-specific analyses, normalized affiliation data,
sensitivity analyses, and clinical validation are required before therapeutic or healthcare
recommendations can be made.
Author Contributions
Conceptualization, Yifei Chen; Methodology, Junjie Ye; Software, Junjie Ye;
Formal analysis, Yifei Chen; Data curation, Yifei Chen; Writing—original draft preparation,
Yifei Chen; Writing—review and editing, Yifei Chen, Jia Lu, Junjie Ye, Xi Deng and Qiyan Zeng;
Article polishing, Jia Lu; Supervision, Yifei Chen and Qiyan Zeng; Funding acquisition, Qiyan
Zeng.
Funding
This research was funded by the National Natural Science Foundation of China (Grant No.
82260592).
Data availability statement
The data used in this study were retrieved from the Web of Science database using publicly
available search terms. All bibliographic data analyzed are available from Web of Science (https://www.webofscience.com,
accessed on December 8, 2025) and were processed using VOSviewer software (version 1.6.20) and
CiteSpace (version 6.4. R1) and Bibliometrix (version 5.2.1). No additional datasets were
generated or analyzed during the study.
Acknowledgements
The authors sincerely thank the Laboratory of Biochemistry and Molecular Biology at the Basic
Medical College of Guangxi Medical University for providing an experimental platform and
technical support throughout this study. We are grateful to all laboratory members for their
constructive suggestions and helpful discussions.
Conflicts of interest
The authors declare that they have no conflicts of interest.